Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting

Core Insights - Cogent Biosciences, Inc. is set to present a poster on bezuclastinib at the 2025 AAAAI Annual Meeting, focusing on its efficacy and safety in patients with Non-Advanced Systemic Mastocytosis [1][3] Company Overview - Cogent Biosciences specializes in developing precision therapies for genetically defined diseases, with bezuclastinib being its most advanced clinical program [4] - Bezuclastinib is a selective tyrosine kinase inhibitor targeting the KIT D816V mutation, which is linked to systemic mastocytosis and other cancers [4] - The company is also conducting a Phase 1 study of a novel FGFR2 inhibitor and developing therapies targeting mutations in ErbB2, PI3Kα, and KRAS [4] Presentation Details - The poster presentation titled "Efficacy and Safety Results of Adult Patients with NonAdvanced Systemic Mastocytosis Receiving Bezuclastinib 100 mg in the Ongoing Summit Trial" will take place on March 1, 2025 [3] - The session will highlight the benefits of long-term use of 100mg bezuclastinib over at least 48 weeks [2] - The presentation is scheduled for 9:45am – 10:45am PT at the San Diego Convention Center [3]